Osterweis Capital Management Inc. Increases Position in Repligen Co. (NASDAQ:RGEN)

Osterweis Capital Management Inc. boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 15.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 61,685 shares of the biotechnology company's stock after buying an additional 8,240 shares during the quarter. Osterweis Capital Management Inc. owned approximately 0.11% of Repligen worth $8,879,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock worth $734,251,000 after purchasing an additional 56,723 shares in the last quarter. Alliancebernstein L.P. increased its position in Repligen by 23.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock worth $145,508,000 after buying an additional 191,439 shares in the last quarter. Conestoga Capital Advisors LLC raised its stake in shares of Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock worth $136,395,000 after buying an additional 6,872 shares during the period. New York State Common Retirement Fund lifted its position in shares of Repligen by 2.5% during the 4th quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company's stock valued at $83,693,000 after buying an additional 14,398 shares in the last quarter. Finally, Stephens Investment Management Group LLC grew its stake in shares of Repligen by 7.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock valued at $77,267,000 after acquiring an additional 37,057 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Repligen

In related news, Director Margaret Pax bought 250 shares of the stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on RGEN shares. Royal Bank of Canada upped their price target on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday, February 21st. TD Cowen initiated coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective for the company. Canaccord Genuity Group decreased their target price on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research note on Wednesday, April 16th. JPMorgan Chase & Co. lifted their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Finally, StockNews.com downgraded shares of Repligen from a "hold" rating to a "sell" rating in a research report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $176.82.

Repligen Stock Performance

Shares of NASDAQ RGEN traded up $7.69 during midday trading on Tuesday, reaching $139.33. The company had a trading volume of 505,650 shares, compared to its average volume of 707,551. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The business's 50-day simple moving average is $140.09 and its 200 day simple moving average is $145.74. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The stock has a market cap of $7.82 billion, a P/E ratio of -273.57, a P/E/G ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million during the quarter, compared to analysts' expectations of $167.58 million. On average, analysts forecast that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.